Clinical trials: Moderate Dementia
Dementia
Dyadic Personalized Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge
This interventional study aims to evaluate the efficacy of a dyadic personalized home-based activity program in managing behavioral and psychological symptoms of dementia (BPSD) among home-dwelling people living with…
- Trial name
- NCT07081750
- Testing
- Dyadic personalized home-based activity program intervention, Routine care
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fujian Medical University
Alzheimer Disease
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life
Therapeutic education expands in Alzheimer's Disease management in France. Several studies revealed a positive impact on caregiver's burden and/or quality of life.
- Trial name
- THERAD (NCT01796314)
- Testing
- Therapeutic Educational Program
- Where
- France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Toulouse
Dementia, Alzheimer's Disease
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
- Trial name
- NCT00104273
- Testing
- Rasagiline
- Where
- 58 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer Disease
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.
- Trial name
- NCT04735536
- Testing
- CT1812
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Cognition Therapeutics
Alzheimer's Disease
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more…
- Trial name
- NCT05908695
- Testing
- GV-971
- Where
- 50 sites in China
- Volunteers
- 1,312 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease (AD)
Recombinant Human Serum Albumin in the Treatment of Mild-to-moderate AD (Alzheimer's Disease) Exploratory Clinical Trial
This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin in patients with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT06489015
- Testing
- Recombinant Human Serum Albumin
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Protgen Co., Ltd.
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics
Mild to Moderate Alzheimer's Disease
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.
- Trial name
- NCT03625622
- Testing
- AR1001
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- AriBio Co., Ltd.
Mild to Moderate Alzheimer's Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
- Trial name
- NCT03507790
- Testing
- CT1812
- Where
- 32 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- Cognition Therapeutics
Alzheimer Disease
Phase II Clinical Trial of Interleukin-2 in AD
Neuroinflammation is a significant component of Alzheimer disease (AD). Our group recently demonstrated that regulatory T cells (Tregs) have a compromised phenotype and reduced suppressive function in AD patients, skewing the…
- Trial name
- NCT06096090
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Caregiver Burnout
Health enSuite Caregivers: an App-based Treatment for Distressed Caregivers of Persons With Moderate Dementia
Health enSuite Caregivers is an e-health program designed to meet some of the most common needs of caregivers of persons with dementia, including information about dementia and dementia care, caregivers' emotional health, formal…
- Trial name
- NCT04944420
- Testing
- Health enSuite Caregivers
- Volunteers
- 400 people
- Sponsor
- IWK Health Centre
Alzheimer's Disease
Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease
This research study will assess whether AAB-001 is safe, well tolerated and effective for use in patients with Alzheimer's Disease. AAB-001 is a new drug that is not available outside this study.
- Trial name
- NCT00174525
- Testing
- AAB-001
- Where
- 2 sites in United States
- Sponsor
- Pharmacology Research Institute
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969123
- Testing
- Drug: EVP-6124
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 474 people
- Sponsor
- FORUM Pharmaceuticals Inc
Alzheimer Disease
Alzheimer's Disease Stem Cells Multiple Infusions
The purpose of this research study is to test the safety, possible side effects, and possible effectiveness of mesenchymal stem cell infusions when given to people with a diagnosis of mild to moderate Alzheimer's disease.
- Trial name
- NCT04040348
- Testing
- Approximately 100 million cells allogeneic hMSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Bernard (Barry) Baumel
Alzheimer Disease
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Trial name
- NCT05295615
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Herrick Medical LLC
Alzheimer's Disease, Dementia
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or…
- Trial name
- NCT01969136
- Testing
- Drug: EVP-6124
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 403 people
- Sponsor
- FORUM Pharmaceuticals Inc
Dementia, Mild, Dementia Moderate
Effect of the Group-based Paro Intervention on Physiological and Psychological Outcomes
This project contains three studies. This study will use a pilot randomized controlled trial to examine the effect of Paro (social robot) intervention on oxytocin, dopamine, and HRV variations and mental well-being for specific…
- Conditions
- Dementia, Mild, Dementia Moderate, Cognitive Impairment
- Trial name
- NCT05102201
- Testing
- Paro (social robot) intervention
- Where
- Taiwan
- Volunteers
- 118 people
- Sponsor
- National Tainan Junior College of Nursing
Alzheimer's Disease
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
Primary Objective: To assess the safety and tolerability of escalating single and multiple doses of SAR228810 in patients with Alzheimer's disease (AD) Secondary Objective: To evaluate the pharmacokinetic properties of SAR228810…
- Trial name
- NCT01485302
- Testing
- SAR228810
- Where
- 8 sites in Bulgaria, France and 3 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Alzheimer's Disease
Bexarotene Amyloid Treatment for Alzheimer's Disease
Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and removal.
- Trial name
- BEAT-AD (NCT01782742)
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic